Dacarbazine
- Generic Name
- Dacarbazine
- Drug Type
- Small Molecule
- Chemical Formula
- C6H10N6O
- CAS Number
- 4342-03-4
- Unique Ingredient Identifier
- 7GR28W0FJI
- Background
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
- Indication
For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma
- Conditions
- Melanoma (Skin)
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 46
- Registration Number
- NCT00004141
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 854
- Registration Number
- NCT00003389
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 260
- Registration Number
- NCT00025064
- Locations
- 🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom
🇬🇧Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom
🇬🇧Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma
- Conditions
- Neuroblastoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- German Society for Pediatric Oncology and Hematology GPOH gGmbH
- Registration Number
- NCT00017225
- Locations
- 🇩🇪
Carl - Thiem - Klinkum Cottbus, Cottbus, Germany
🇩🇪Klinikum Lippe - Detmold, Detmold, Germany
🇩🇪Praxis am Evangelischen Krankenhaus Bethanien, Iserlohn, Germany
Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Mount Vernon Cancer Centre at Mount Vernon Hospital
- Target Recruit Count
- 850
- Registration Number
- NCT00041210
- Locations
- 🇬🇧
Pinderfields General Hospital, Wakefield, Scotland, United Kingdom
🇬🇧Aintree University Hospital, Liverpool, England, United Kingdom
🇬🇧City Hospital - Birmingham, West Bromwich, England, United Kingdom
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
- Conditions
- Melanoma (Skin)
- Interventions
- Biological: interleukin-2Biological: filgrastimBiological: interferon alfa
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 432
- Registration Number
- NCT00006237
- Locations
- 🇺🇸
George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus, New Britain, Connecticut, United States
🇺🇸Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States
🇺🇸Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
- Conditions
- MelanomaSkin Cancer
- Interventions
- Biological: Recombinant Interferon Alfa (IFN-A)Biological: Aldesleukin (IL-2)Procedure: Adjuvant Therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 140
- Registration Number
- NCT00002882
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus
- Conditions
- Sarcoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00033644
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸Tuft-New England Medical Center, Boston, Massachusetts, United States
Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy
- Conditions
- Hodgkin Disease
- Interventions
- First Posted Date
- 2002-06-03
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00038558
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease
- Conditions
- HIV InfectionsHodgkin's Disease
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-27
- Target Recruit Count
- 27
- Registration Number
- NCT00000626
- Locations
- 🇺🇸
St. Louis ConnectCare, Infectious Diseases Clinic, Saint Louis, Missouri, United States
🇺🇸SUNY - Buffalo, Erie County Medical Ctr., Buffalo, New York, United States
🇺🇸The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.